KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Cash at End of Period

Last Annual Value

98.05M

3-Year CAGR

218%

5-Year CAGR

-4%

10-Year CAGR

-2%

KT

Kalaris Therapeutics Inc Competitors Analysis of Cash at End of Period

KLRS · NASDAQ
CompanyCash at End of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
98.05M
213.9%-13.4%N/A 
15.08M
-19.6%-39.6%-11.6%
27.16M
-20.4%-30.0%N/A
54.19M
-24.4%-10.1%N/A
66.00M
65.9%5.8%N/A
46.91M
-31.5%1.6%N/A
62.63M
-6.6%11.3%-11.9%
16.44M
-9.9%-46.2%N/A
85.80M
31.4%-2.1%N/A
48.94M
-20.2%2.6%N/A
45.95M
71.8%-9.9%28.0%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66